2020-10-02 Artykuł

Hormonalna terapia zastępcza testosteronem u mężczyzn

Testosteron jest głównym męskim hormonem płciowym, niezbędnym do różnicowania płciowego i rozwoju oraz utrzymania męskiego fenotypu. Pełni także kluczową rolę w męskich funkcjach rozrodczych i seksualnych. Podobnie jak u kobiet w okresie menopauzy, u mężczyzn z wiekiem lub w następstwie procesów chorobowych dochodzi do zmian hormonalnych. Po 40. r.ż. stężenie testosteronu obniża się o 2-4% na rok. Niedobór testosteronu może być bezobjawowy, ale z upływem czasu często prowadzi do wystąpienia objawów klinicznych, takich jak zmniejszenie masy mięśniowej i siły mięśni, utrata masy kostnej, osteoporoza oraz wzrost zawartości tkanki tłuszczowej.
Wraz ze wzrostem średniej długości życia mężczyzn na całym świecie i rosnącym problemem andropauzy, zainteresowanie testosteronem znacząco wzrosło. Na wzór hormonalnej terapii zastępczej u kobiet rozpoczęto stosowanie podobnej u mężczyzn. Hormonalna terapia zastępcza testosteronem polega na egzogennym podaniu testosteronu, którego zadaniem jest przywrócenie fizjologicznego stężenia testosteronu u mężczyzny z jego niedoborem. Badania pokazują, że wyrównanie niedoborów testosteronu znacząco łagodzi pojawiające się objawy kliniczne. Obecnie dostępnych jest wiele sposobów podaży
testosteronu. Ze względu na drogę podania wyróżnia się formę: doustną, domięśniową, przezskórną, podjęzykową i podpoliczkową, podskórną oraz donosową.
  Czytaj pełny tekst

Autor:  Edyta Jankowiak,  Jakub Kościński, dr hab. n. med., prof. UMK Michał Wiciński

Udostępnij:

Data publikacji: 2020-10-02

Źródło: "Gabinet Prywatny" nr 04/2020

Słowa kluczowe: testosteron, suplementacja, hormonalna terapia zastępcza testosteronem

  1. Miah S, Tharakan T, Gallagher KA, Shah TT, Winkler M, Jayasena CN, Ahmed HU, Minhas S. The effects of testosterone replacement therapy on the prostate: a clinical perspective. F1000Res. 2019;8. doi: 10.12688/f1000research.16497.1.
  2. Corona G, Sforza A, Maggi M. Testosterone Replacement Therapy: Long-Term Safety and Efficacy. World J Mens Health. 2017 Aug;35(2):65-76. doi: 10.5534/wjmh.2017.35.2.65.
  3. FDA (U.S. Food and Drug Administration) – FDA approves new oral testosterone capsule for treatment of men with certain forms of hypogonadism, 27 March 2020.
  4. Shoskes JJ, Wilson MK, Spinner ML. Pharmacology of testosterone replacement therapy preparations. Transl Androl Urol. 2016 Dec;5(6):834-843. doi: 10.21037/tau.2016.07.10. Review.
  5. Yassin AA, Haffejee M. Testosterone depot injection in male hypogonadism: a critical appraisal. Clin Interv Aging. 2007;2(4):577-90. Review.
  6. Lakshman KM, Basaria S. Safety and efficacy of testosterone gel in the treatment of male hypogonadism. Clin Interv Aging. 2009;4:397-412. doi: 10.2147/cia.s4466.
  7. Salehian B, Wang C, Alexander G, Davidson T, McDonald V, Berman N, Dudley RE, Ziel F, Swerdloff RS. Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study. J Clin Endocrinol Metab. 1995 Dec;80(12):3567-75. doi: 10.1210/jcem.80.12.8530600. 
  8. Korbonits M, Slawik M, Cullen D, Ross RJ, Stalla G, Schneider H, Reincke M, Bouloux PM, Grossman AB. A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males. J Clin Endocrinol Metab. 2004 May;89(5):2039-43. doi: 10.1210/jc.2003-030319.
  9. Kelleher S, Conway AJ, Handelsman DJ. Influence of implantation site and track geometry on the extrusion rate and pharmacology of testosterone implants. Clin Endocrinol (Oxf). 2001 Oct;55(4):531-6. doi: 10.1046/j.1365-2265.2001.01357.x.
  10. Natesto™ [package insert]. Malvern (PA): Endo Pharmaceuticals; May 2015.
  11. Dohle GR, Arver S, Bettocchi C, Jones TH, Kliesch S. Guidelines on male hypogonadism. Eur Assoc Urol 2017.
  12. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O'Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010 Jul 8;363(2):123-35. doi: 10.1056/NEJMoa0911101.
  13. Kelleher S, Conway AJ, Handelsman DJ. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab. 2004 Aug;89(8):3813-7. doi: 10.1210/jc.2004-0143.
  14. Bhasin S, Pencina M, Jasuja GK, Travison TG, Coviello A, Orwoll E, Wang PY, Nielson C, Wu F, Tajar A, Labrie F, Vesper H, Zhang A, Ulloor J, Singh R, D'Agostino R, Vasan RS. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab. 2011 Aug;96(8):2430-9. doi: 10.1210/jc.2010-3012.
  15. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, S werdloff RS, Montori VM. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010 Jun;95(6):2536-59. doi: 10.1210/jc.2009-2354. Review.
  16. Sartorius G, Spasevska S, Idan A, Turner L, Forbes E, Zamojska A, Allan CA, Ly LP, Conway AJ, McLachlan RI, Handelsman DJ. Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: the healthy man study. Clin Endocrinol (Oxf). 2012 Nov;77(5):755-63. doi: 10.1111/j.1365-2265.2012.04432.x.
  17. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol. 2008 Nov;159(5):507-14. doi: 10.1530/EJE-08-0601. 
  18. Clarke BL, Khosla S. Androgens and bone. Steroids. 2009 Mar;74(3):296-305. doi: 10.1016/j.steroids.2008.10.003.
  19. Sözen T, Özışık L, Başaran NÇ. An overview and management of osteoporosis. Eur J Rheumatol. 2017 Mar;4(1):46-56. doi: 10.5152/eurjrheum.2016.048. Epub 2016 Dec 30.
  20. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 1997 Aug;82(8):2386-90. doi: 10.1210/jcem.82.8.4163.
  21. Basurto L, Zarate A, Gomez R, Vargas C, Saucedo R, Galván R. Effect of testosterone therapy on lumbar spine and hip mineral density in elderly men. Aging Male. 2008 Sep;11(3):140-5. doi: 10.1080/13685530802273715.
  22. Jo DG, Lee HS, Joo YM, Seo JT. Effect of testosterone replacement therapy on bone mineral density in patients with Klinefelter syndrome. Yonsei Med J. 2013 Nov;54(6):1331-5. doi: 10.3349/ymj.2013.54.6.1331.
  23. Ferrando AA, Sheffield-Moore M, Yeckel CW, Gilkison C, Jiang J, Achacosa A, Lieberman SA, Tipton K, Wolfe RR, Urban RJ. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab. 2002 Mar;282(3):E601-7. doi: 10.1152/ajpendo.00362.2001.
  24. Meier C, Nguyen TV, Handelsman DJ, Schindler C, Kushnir MM, Rockwood AL, Meikle AW, Center JR, Eisman JA, Seibel MJ. Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med. 2008 Jan 14;168(1):47-54. doi: 10.1001/archinternmed.2007.2.
  25. Vingren JL, Kraemer WJ, Ratamess NA, Anderson JM, Volek JS, Maresh CM. Testosterone physiology in resistance exercise and training: the up-stream regulatory elements. Sports Med. 2010 Dec 1;40(12):1037-53. doi: 10.2165/11536910-000000000-00000.
  26. Storer TW, Woodhouse L, Magliano L, Singh AB, Dzekov C, Dzekov J, Bhasin S. Changes in muscle mass, muscle strength, and power but not physical function are related to testosterone dose in healthy older men. J Am Geriatr Soc. 2008 Nov;56(11):1991-9. doi: 10.1111/j.1532-5415.2008.01927.x.
  27. Srinivas-Shankar U, Roberts SA, Connolly MJ, O'Connell MD, Adams JE, Oldham JA, Wu FC. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010 Feb;95(2):639-50. doi: 10.1210/jc.2009-1251.
  28. Forbes MK, Eaton NR, Krueger RF. Sexual Quality of Life and Aging: A Prospective Study of a Nationally Representative Sample. J Sex Res. 2017 Feb;54(2):137-148. doi: 10.1080/00224499.2016.1233315.
  29. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bremner WJ, McKinlay JB. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002 Feb;87(2):589-98. doi: 10.1210/jcem.87.2.8201.
  30. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000 Feb;163(2):460-3.
  31. Cunningham GR, Stephens-Shields AJ, Rosen RC, Wang C, Bhasin S, Matsumoto AM, Parsons JK, Gill TM, Molitch ME, Farrar JT, Cella D, Barrett-Connor E, Cauley JA, Cifelli D, Crandall JP, Ensrud KE, Gallagher L, Zeldow B, Lewis CE, Pahor M, Swerdloff RS, Hou X, Anton S, Basaria S, Diem SJ, Tabatabaie V, Ellenberg SS, Snyder PJ. Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels. J Clin Endocrinol Metab. 2016 Aug;101(8):3096-104. doi: 10.1210/jc.2016-1645
  32. Rizk PJ, Kohn TP, Pastuszak AW, Khera M. Testosterone therapy improves erectile function and libido in hypogonadal men. Curr Opin Urol. 2017 Nov;27(6):511-515. doi: 10.1097/MOU.0000000000000442.
  33. Loizides E, Swierzewski MJ, O'neill C, Griesser J, Smith T. Early Response Time in Sexual Activity and Mood Following Testosterone Gel Replacement in Hypogonadal Males from the Testim(R) START Study. Rev Urol. 2004;6 Suppl 6:S16-21.
  34. Berglund LH, Prytz HS, Perski A, Svartberg J. Testosterone levels and psychological health status in men from a general population: the Tromsø study. Aging Male. 2011 Mar;14(1):37-41. doi: 10.3109/13685538.2010.
  35. Kheirkhah F, Hosseini SR, Hosseini SF, Ghasemi N, Bijani A, G Cumming R. Relationship between testosterone levels and depressive symptoms in older men in Amirkola, Iran. Caspian J Intern Med. 2014 Spring;5(2):65-70.
  36. Polakovich AS, Tadros NN, Ostrowski KA, Hedges JC. Benefits and Consequences of Testosterone Replacement Therapy: A Review. Eur Endocrinol. 2013 Mar;9(1):59-64.
  37. Amanatkar HR, Chibnall JT, Seo BW, Manepalli JN, Grossberg GT. Impact of exogenous testosterone on mood: a systematic review and meta-analysis of randomized placebo-controlled trials. Ann Clin Psychiatry. 2014 Feb;26(1):19-32.
  38. Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, Steiner B, Hull L, Callegari C, Swerdloff RS. Testosterone replacement therapy improves mood in hypogonadal men--a clinical research center study. J Clin Endocrinol Metab. 1996 Oct;81(10):3578-83. doi: 10.1210/jcem.81.10.8855804.
  39. Spitzer M, Basaria S, Travison TG, Davda MN, DeRogatis L, Bhasin S. The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. Andrology. 2013 May;1(3):475-82. doi: 10.1111/j.2047-2927.2013.00075.x.
  40. Kim C, Barrett-Connor E, Aroda VR, Mather KJ, Christophi CA, Horton ES, Pi-Sunyer X, Bray GA, Labrie F, Golden SH. Testosterone and depressive symptoms among men in the Diabetes Prevention Program. Psychoneuroendocrinology. 2016 Oct;72:63-71. doi: 10.1016/j.psyneuen.2016.06.009.
  41. Muraleedharan V, Jones TH. Testosterone and the metabolic syndrome. Ther Adv Endocrinol Metab. 2010 Oct;1(5):207-23. doi: 10.1177/2042018810390258.
  42. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006 Jun;154(6):899-906. doi: 10.1530/eje.1.02166.
  43. Zumoff B, Strain GW, Miller LK, Rosner W, Senie R, Seres DS, Rosenfeld RS. Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab. 1990 Oct;71(4):929-31. doi: 10.1210/jcem-71-4-929.
  44. Haring R, Baumeister SE, Völzke H, Dörr M, Felix SB, Kroemer HK, Nauck M, Wallaschofski H. Prospective association of low total testosterone concentrations with an adverse lipid profile and increased incident dyslipidemia. Eur J Cardiovasc Prev Rehabil. 2011 Feb;18(1):86-96. doi: 10.1097/HJR.0b013e32833c1a8d. 
  45. Wickramatilake CM, Mohideen MR, Pathirana C. Association of serum testosterone with lipid abnormalities in patients with angiographically proven coronary artery disease. Indian J Endocrinol Metab. 2013 Nov;17(6):1061-5. doi: 10.4103/2230-8210.122624. 
  46. Goodale T, Sadhu A, Petak S, Robbins R. Testosterone and the Heart. Methodist Debakey Cardiovasc J. 2017 Apr-Jun;13(2):68-72. doi: 10.14797/mdcj-13-2-68.
  47. Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, Fraumeni JF Jr, Hoover RN. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9(1):e85805. doi: 10.1371/journal.pone.0085805.
  48. Vigen R, O'Donnell CI, Barón AE, Grunwald GK, Maddox TM, Bradley SM, Barqawi A, Woning G, Wierman ME, Plomondon ME, Rumsfeld JS, Ho PM. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013 Nov 6;310(17):1829-36. doi: 10.1001/jama.2013.280386.
  49. Jarvis TR, Chughtai B, Kaplan SA. Testosterone and benign prostatic hyperplasia. Asian J Androl. 2015 Mar-Apr;17(2):212-6. doi: 10.4103/1008-682X.140966. 
  50. Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf). 1994 Mar;40(3):341-9. doi: 10.1111/j.1365-2265.1994.tb03929.x.
  51. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab. 1992 Oct;75(4):1092-8. doi: 10.1210/jcem.75.4.1400877. 
  52. Raynaud JP, Gardette J, Rollet J, Legros JJ. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment. BJU Int. 2013 May;111(6):880-90. doi: 10.1111/j.1464-410X.2012.11514.x.
  53. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov DV, Partin AW, Bostwick DG, Macairan ML, Nelson PS. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006 Nov 15;296(19):2351-61. doi: 10.1001/jama.296.19.2351.
  54. Morales A. Androgen replacement therapy and prostate safety. Eur Urol. 2002 Feb;41(2):113-20. doi: 10.1016/s0302-2838(01)00039-2.
  55. Baas W, Köhler TS. Testosterone Replacement Therapy and BPH/LUTS. What is the Evidence?. Curr Urol Rep. 2016 Jun;17(6):46. doi: 10.1007/s11934-016-0600-8.
  56. Severi G, Morris HA, MacInnis RJ, English DR, Tilley W, Hopper JL, Boyle P, Giles GG. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):86-91. doi: 10.1158/1055-9965.EPI-05-0633. 
  57. Perlmutter MA, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol. 2007;9 Suppl 1:S3-8.
  58. Marks L.S., Mazer N.A., Mostaghel E., Hess D.L., Dorey F.J., Epstein J.I. i wsp.: Eff ect of testosterone replacement therapy on prostate tissue in men with late -onset hypogonadism: a randomized controlled trial. JAMA. 2006, 296 (19), 2351–2361.
  59. Michaud JE, Billups KL, Partin AW. Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk. Ther Adv Urol. 2015 Dec;7(6):378-87. doi: 10.1177/1756287215597633. 
  60. Rodriguez KM, Pastuszak AW, Khera M. The Role of Testosterone Therapy in the Setting of Prostate Cancer. Curr Urol Rep. 2018 Jun 30;19(8):67. doi: 10.1007/s11934-018-0812-1.
  61. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004 Sep;172(3):920-2. doi: 10.1097/01.ju.0000136269.10161.32.
  62. Morgentaler A, Morales A. Should hypogonadal men with prostate cancer receive testosterone?. J Urol. 2010 Oct;184(4):1257-60. doi: 10.1016/j.juro.2010.07.010. 
  63. Jones SD Jr, Dukovac T, Sangkum P, Yafi FA, Hellstrom WJ. Erythrocytosis and Polycythemia Secondary to Testosterone Replacement Therapy in the Aging Male. Sex Med Rev. 2015 Apr;3(2):101-112. doi: 10.1002/smrj.43.
POWRÓT
reklama Baner_prawy_ZALOGU-SIE_GP
...
Redaktor poleca
reklama KLRwPolsce
Info
reklama MLR_nowe_logo
Najczęściej czytane
reklama STAN PRZEDCUKRZYCOWY_OKŁADKA_XL
GP

Na skróty

Informacje

Copyright © Medyk sp. z o.o